Podjarny E, Bernheim J L, Pomeranz A, Rathaus M, Pomeranz M, Green J, Bernheim J
Department of Nephrology, Meir Hospital, Kfar-Saba, Israel.
Nephrol Dial Transplant. 1993;8(6):501-6. doi: 10.1093/ndt/8.6.501.
Recent studies have suggested that the progression of experimental chronic renal disease may be prevented by early use of antihypertensive drugs. It is unclear, however, whether such therapies may also affect established and progressive renal disease. In the present study we compared the effects of captopril (CEI) and diltiazem (CCB), started either at week 10 or at week 24 on the evolution of adriamycin nephropathy (AN). Rats were studied at weeks 7, 16, 24, 32, and 38 of the disease. None of the treatments influenced the development of nephrotic range proteinuria. The use of CCB from week 10 was even associated with increased proteinuria. The moderate hypertension of ADR rats was reduced to the same degree with both drugs. Inulin clearance (GFR) was significantly reduced in all ADR rats. However, in ADR rats treated with CEI from week 10 and in those treated with CCB from week 24, the GFR was relatively higher. Glomerular injury, evaluated by semiquantitative methods, was not ameliorated by CEI treatment. Earlier CCB treatment (week 10) worsened glomerular lesions, whilst CCB treatment initiated at week 24 reduced significantly the degree of mesangial expansion and focal glomerular sclerosis. We conclude that, in addition to their common antihypertensive action, the specific effect of drug therapy seems to be crucially time dependent.
最近的研究表明,早期使用抗高血压药物可能会阻止实验性慢性肾病的进展。然而,尚不清楚此类疗法是否也会影响已确诊的进行性肾病。在本研究中,我们比较了在第10周或第24周开始使用卡托普利(CEI)和地尔硫䓬(CCB)对阿霉素肾病(AN)进展的影响。在疾病的第7、16、24、32和38周对大鼠进行研究。没有一种治疗方法影响肾病范围蛋白尿的发展。从第10周开始使用CCB甚至与蛋白尿增加有关。两种药物都能将ADR大鼠的中度高血压降低到相同程度。所有ADR大鼠的菊粉清除率(GFR)均显著降低。然而,在从第10周开始用CEI治疗的ADR大鼠和从第24周开始用CCB治疗的大鼠中,GFR相对较高。通过半定量方法评估的肾小球损伤并未因CEI治疗而改善。早期CCB治疗(第10周)会使肾小球病变恶化,而在第24周开始的CCB治疗则显著降低了系膜扩张和局灶性肾小球硬化的程度。我们得出结论,除了它们共同的抗高血压作用外,药物治疗的特定效果似乎关键取决于时间。